Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

Association of Ultraviolet Radiation Exposure with Dermatomyositis in a National Myositis Patient Registry.

Parks CG, Wilkerson J, Rose KM, Faiq A, Noroozi Farhadi P, Long CS, Bayat N, Brunner HI, Goldberg B, McGrath JA, Miller FW, Rider LG.

Arthritis Care Res (Hoboken). 2019 Sep 3. doi: 10.1002/acr.24059. [Epub ahead of print]

PMID:
31478597
2.

Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis.

Kishi T, Chipman J, Evereklian M, Nghiem K, Stetler-Stevenson M, Rick ME, Centola M, Miller FW, Rider LG.

J Rheumatol. 2019 Aug 1. pii: jrheum.181275. doi: 10.3899/jrheum.181275. [Epub ahead of print]

PMID:
31371656
3.

Long-term outcomes in Juvenile Myositis patients.

Tsaltskan V, Aldous A, Serafi S, Yakovleva A, Sami H, Mamyrova G, Targoff IN, Schiffenbauer A, Miller FW, Simmens SJ, Curiel R, Jones OY, Rider LG.

Semin Arthritis Rheum. 2019 Jun 28. pii: S0049-0172(19)30136-2. doi: 10.1016/j.semarthrit.2019.06.014. [Epub ahead of print]

PMID:
31303436
4.

Loss of MAP3K7 Sensitizes Prostate Cancer Cells to CDK1/2 Inhibition and DNA Damage by Disrupting Homologous Recombination.

Washino S, Rider LC, Romero L, Jillson LK, Affandi T, Ohm AM, Lam ET, Reyland ME, Costello JC, Cramer SD.

Mol Cancer Res. 2019 Jul 12. doi: 10.1158/1541-7786.MCR-18-1335. [Epub ahead of print]

PMID:
31300540
5.

Response to: 'response to: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis' by Sabbagh S et al' by Yang et al.

Sabbagh S, Pinal Fernandez I, Miller FW, Rider LG, Mammen AL.

Ann Rheum Dis. 2019 Jun 17. pii: annrheumdis-2019-215693. doi: 10.1136/annrheumdis-2019-215693. [Epub ahead of print] No abstract available.

PMID:
31208959
6.

Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups.

Rothwell S, Chinoy H, Lamb JA, Miller FW, Rider LG, Wedderburn LR, McHugh NJ, Mammen AL, Betteridge ZE, Tansley SL, Bowes J, Vencovský J, Deakin CT, Dankó K, Vidya L, Selva-O'Callaghan A, Pachman LM, Reed AM, Molberg Ø, Benveniste O, Mathiesen PR, Radstake TRDJ, Doria A, de Bleecker J, Lee AT, Hanna MG, Machado PM, Ollier WE, Gregersen PK, Padyukov L, O'Hanlon TP, Cooper RG, Lundberg IE; Myositis Genetics Consortium (MYOGEN).

Ann Rheum Dis. 2019 Jul;78(7):996-1002. doi: 10.1136/annrheumdis-2019-215046. Epub 2019 May 28.

7.

Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis.

Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group.

Ann Rheum Dis. 2019 Jul;78(7):988-995. doi: 10.1136/annrheumdis-2018-215004. Epub 2019 Apr 24.

PMID:
31018961
8.

Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis.

Mamyrova G, Kishi T, Targoff IN, Ehrlich A, Curiel RV, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.

Rheumatology (Oxford). 2018 Nov 1;57(11):1956-1963. doi: 10.1093/rheumatology/key190.

PMID:
30016492
9.

Pediatric Rheumatology Collaborative Study Group - over four decades of pivotal clinical drug research in pediatric rheumatology.

Brunner HI, Rider LG, Kingsbury DJ, Co D, Schneider R, Goldmuntz E, Onel KB, Giannini EH, Lovell DJ; PRCSG Advisory Council.

Pediatr Rheumatol Online J. 2018 Jul 11;16(1):45. doi: 10.1186/s12969-018-0261-x. Review.

10.

Medications received by patients with juvenile dermatomyositis.

Kishi T, Bayat N, Ward MM, Huber AM, Wu L, Mamyrova G, Targoff IN, Warren-Hicks WJ, Miller FW, Rider LG; Childhood Myositis Heterogeneity Study Group.

Semin Arthritis Rheum. 2018 Dec;48(3):513-522. doi: 10.1016/j.semarthrit.2018.03.016. Epub 2018 Mar 28.

PMID:
29773230
11.

Update on outcome assessment in myositis.

Rider LG, Aggarwal R, Machado PM, Hogrel JY, Reed AM, Christopher-Stine L, Ruperto N.

Nat Rev Rheumatol. 2018 May;14(5):303-318. doi: 10.1038/nrrheum.2018.33. Epub 2018 Apr 12. Review.

12.
13.

Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.

Yeker RM, Pinal-Fernandez I, Kishi T, Pak K, Targoff IN, Miller FW, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group.

Ann Rheum Dis. 2018 May;77(5):714-719. doi: 10.1136/annrheumdis-2017-212436. Epub 2018 Jan 23.

14.

EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report.

Bottai M, Tjärnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, García-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinka M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Wook Song Y, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, Lundberg IE; International Myositis Classification Criteria Project consortium, the Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland) .

RMD Open. 2017 Nov 14;3(2):e000507. doi: 10.1136/rmdopen-2017-000507. eCollection 2017.

15.

2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups.

Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Garcia-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland).

Arthritis Rheumatol. 2017 Dec;69(12):2271-2282. doi: 10.1002/art.40320. Epub 2017 Oct 27. Erratum in: Arthritis Rheumatol. 2018 Sep;70(9):1532.

16.

Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research.

McCann LJ, Pilkington CA, Huber AM, Ravelli A, Appelbe D, Kirkham JJ, Williamson PR, Aggarwal A, Christopher-Stine L, Constantin T, Feldman BM, Lundberg I, Maillard S, Mathiesen P, Murphy R, Pachman LM, Reed AM, Rider LG, van Royen-Kerkof A, Russo R, Spinty S, Wedderburn LR, Beresford MW.

Ann Rheum Dis. 2018 Feb;77(2):241-250. doi: 10.1136/annrheumdis-2017-212141. Epub 2017 Oct 30.

17.

2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.

Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG; International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland).

Ann Rheum Dis. 2017 Dec;76(12):1955-1964. doi: 10.1136/annrheumdis-2017-211468. Epub 2017 Oct 27. Erratum in: Ann Rheum Dis. 2018 Sep;77(9):e64.

18.

2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects.

Rider LG, Ruperto N, Pistorio A, Erman B, Bayat N, Lachenbruch PA, Rockette H, Feldman BM, Huber AM, Hansen P, Oddis CV, Lundberg IE, Amato AA, Chinoy H, Cooper RG, Chung L, Danko K, Fiorentino D, García-De la Torre I, Reed AM, Wook Song Y, Cimaz R, Cuttica RJ, Pilkington CA, Martini A, van der Net J, Maillard S, Miller FW, Vencovsky J, Aggarwal R; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.

Rheumatology (Oxford). 2017 Nov 1;56(11):1884-1893. doi: 10.1093/rheumatology/kex226.

19.

Environmental factors associated with disease flare in juvenile and adult dermatomyositis.

Mamyrova G, Rider LG, Ehrlich A, Jones O, Pachman LM, Nickeson R, Criscone-Schreiber LG, Jung LK, Miller FW, Katz JD.

Rheumatology (Oxford). 2017 Aug 1;56(8):1342-1347. doi: 10.1093/rheumatology/kex162.

20.

Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists.

Tiao J, Feng R, Berger EM, Brandsema JF, Coughlin CC, Khan N, Kichula EA, Lerman MA, Lvovich S, McMahon PJ, Rider LG, Rubin AI, Scalzi LV, Smith DM, Taxter AJ, Treat JR, Williams RP, Yum SW, Okawa J, Werth VP.

Br J Dermatol. 2017 Oct;177(4):1086-1092. doi: 10.1111/bjd.15596. Epub 2017 Jul 31.

21.

2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, García-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.

Ann Rheum Dis. 2017 May;76(5):792-801. doi: 10.1136/annrheumdis-2017-211400.

22.

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Saad Magalhaes C, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J, Ruperto N; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.

Ann Rheum Dis. 2017 May;76(5):782-791. doi: 10.1136/annrheumdis-2017-211401. Erratum in: Ann Rheum Dis. 2018 Apr;77(4):623.

23.

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, García-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.

Arthritis Rheumatol. 2017 May;69(5):898-910. doi: 10.1002/art.40064. Epub 2017 Apr 6.

24.

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Magalhaes CS, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J, Ruperto N; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.

Arthritis Rheumatol. 2017 May;69(5):911-923. doi: 10.1002/art.40060. Epub 2017 Apr 6. Erratum in: Arthritis Rheumatol. 2018 Mar;70(3):467.

25.

Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients.

Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, Shaham B, Weiss PF, Horkayne-Szakaly I, Targoff IN, Miller FW, Mammen AL; Childhood Myositis Heterogeneity Study Group.

Arthritis Care Res (Hoboken). 2017 Jul;69(7):1088-1094. doi: 10.1002/acr.23113.

26.

Predictors of Reduced Health-Related Quality of Life in Adult Patients With Idiopathic Inflammatory Myopathies.

Feldon M, Farhadi PN, Brunner HI, Itert L, Goldberg B, Faiq A, Wilkerson J, Rose KM, Rider LG, Miller FW, Giannini EH.

Arthritis Care Res (Hoboken). 2017 Nov;69(11):1743-1750. doi: 10.1002/acr.23198. Epub 2017 Sep 21.

27.

Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease.

Kim S, Kahn P, Robinson AB, Lang B, Shulman A, Oberle EJ, Schikler K, Curran ML, Barillas-Arias L, Spencer CH, Rider LG, Huber AM.

Pediatr Rheumatol Online J. 2017 Jan 11;15(1):1. doi: 10.1186/s12969-016-0134-0.

28.

CD3Z hypermethylation is associated with severe clinical manifestations in systemic lupus erythematosus and reduces CD3ζ-chain expression in T cells.

Hong KM, Kim HK, Park SY, Poojan S, Kim MK, Sung J, Tsao BP, Grossman JM, Rullo OJ, Woo JM, McCurdy DK, Rider LG, Miller FW, Song YW.

Rheumatology (Oxford). 2017 Mar 1;56(3):467-476. doi: 10.1093/rheumatology/kew405.

29.

213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015.

Benveniste O, Rider LG; ENMC Myositis Outcomes Study Group.

Neuromuscul Disord. 2016 Aug;26(8):523-34. doi: 10.1016/j.nmd.2016.05.014. Epub 2016 May 27. No abstract available.

30.

Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients.

Nagaraju K, Ghimbovschi S, Rayavarapu S, Phadke A, Rider LG, Hoffman EP, Miller FW.

Rheumatology (Oxford). 2016 Sep;55(9):1673-80. doi: 10.1093/rheumatology/kew213. Epub 2016 May 23.

31.

The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes.

Rider LG, Nistala K.

J Intern Med. 2016 Jul;280(1):24-38. doi: 10.1111/joim.12444. Epub 2016 Mar 30. Review.

32.

Proposal for a Candidate Core Set of Fitness and Strength Tests for Patients with Childhood or Adult Idiopathic Inflammatory Myopathies.

van der Stap DK, Rider LG, Alexanderson H, Huber AM, Gualano B, Gordon P, van der Net J, Mathiesen P, Johnson LG, Ernste FC, Feldman BM, Houghton KM, Singh-Grewal D, Kutzbach AG, Alemo Munters L, Takken T; International Myositis Assessment and Clinical Studies Group.

J Rheumatol. 2016 Jan;43(1):169-76. doi: 10.3899/jrheum.150270. Epub 2015 Nov 15. Review.

33.

Gene Expression Profiles from Disease Discordant Twins Suggest Shared Antiviral Pathways and Viral Exposures among Multiple Systemic Autoimmune Diseases.

Gan L, O'Hanlon TP, Lai Z, Fannin R, Weller ML, Rider LG, Chiorini JA, Miller FW.

PLoS One. 2015 Nov 10;10(11):e0142486. doi: 10.1371/journal.pone.0142486. eCollection 2015.

34.

SPOP the mutation.

Rider L, Cramer SD.

Elife. 2015 Oct 27;4. pii: e11760. doi: 10.7554/eLife.11760.

35.

Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis.

Lintner KE, Patwardhan A, Rider LG, Abdul-Aziz R, Wu YL, Lundström E, Padyukov L, Zhou B, Alhomosh A, Newsom D, White P, Jones KB, O'Hanlon TP, Miller FW, Spencer CH, Yu CY.

Ann Rheum Dis. 2016 Sep;75(9):1599-606. doi: 10.1136/annrheumdis-2015-207762. Epub 2015 Oct 22.

36.

Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis.

Habers GE, Huber AM, Mamyrova G, Targoff IN, O'Hanlon TP, Adams S, Pandey JP, Boonacker C, van Brussel M, Miller FW, van Royen-Kerkhof A, Rider LG; Childhood Myositis Heterogeneity Study Group.

Arthritis Rheumatol. 2016 Mar;68(3):761-8. doi: 10.1002/art.39466.

37.

Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies.

Yao L, Yip AL, Shrader JA, Mesdaghinia S, Volochayev R, Jansen AV, Miller FW, Rider LG.

Rheumatology (Oxford). 2016 Mar;55(3):441-9. doi: 10.1093/rheumatology/kev344. Epub 2015 Sep 27.

38.

Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups.

Rothwell S, Cooper RG, Lundberg IE, Miller FW, Gregersen PK, Bowes J, Vencovsky J, Danko K, Limaye V, Selva-O'Callaghan A, Hanna MG, Machado PM, Pachman LM, Reed AM, Rider LG, Cobb J, Platt H, Molberg Ø, Benveniste O, Mathiesen P, Radstake T, Doria A, De Bleecker J, De Paepe B, Maurer B, Ollier WE, Padyukov L, O'Hanlon TP, Lee A, Amos CI, Gieger C, Meitinger T, Winkelmann J, Wedderburn LR, Chinoy H, Lamb JA; Myositis Genetics Consortium.

Ann Rheum Dis. 2016 Aug;75(8):1558-66. doi: 10.1136/annrheumdis-2015-208119. Epub 2015 Sep 11.

39.

Chimeric cells of maternal origin do not appear to be pathogenic in the juvenile idiopathic inflammatory myopathies or muscular dystrophy.

Artlett CM, Sassi-Gaha S, Ramos RC, Miller FW, Rider LG.

Arthritis Res Ther. 2015 Sep 4;17:238. doi: 10.1186/s13075-015-0732-0.

40.

Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes.

Miller FW, Chen W, O'Hanlon TP, Cooper RG, Vencovsky J, Rider LG, Danko K, Wedderburn LR, Lundberg IE, Pachman LM, Reed AM, Ytterberg SR, Padyukov L, Selva-O'Callaghan A, Radstake TR, Isenberg DA, Chinoy H, Ollier WE, Scheet P, Peng B, Lee A, Byun J, Lamb JA, Gregersen PK, Amos CI; Myositis Genetics Consortium.

Genes Immun. 2015 Oct;16(7):470-80. doi: 10.1038/gene.2015.28. Epub 2015 Aug 20.

41.

Do solar cycles influence giant cell arteritis and rheumatoid arthritis incidence?

Wing S, Rider LG, Johnson JR, Miller FW, Matteson EL, Crowson CS, Gabriel SE.

BMJ Open. 2015 May 15;5(5):e006636. doi: 10.1136/bmjopen-2014-006636.

42.

Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer.

Rodrigues LU, Rider L, Nieto C, Romero L, Karimpour-Fard A, Loda M, Lucia MS, Wu M, Shi L, Cimic A, Sirintrapun SJ, Nolley R, Pac C, Chen H, Peehl DM, Xu J, Liu W, Costello JC, Cramer SD.

Cancer Res. 2015 Mar 15;75(6):1021-34. doi: 10.1158/0008-5472.CAN-14-1596.

43.

The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.

Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG.

Curr Rheumatol Rep. 2014 Dec;16(12):467. doi: 10.1007/s11926-014-0467-y. Review.

44.

Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.

Rider LG, Dankó K, Miller FW.

Curr Opin Rheumatol. 2014 Nov;26(6):724-41. doi: 10.1097/BOR.0000000000000119. Review.

45.

Lipid catabolism via CPT1 as a therapeutic target for prostate cancer.

Schlaepfer IR, Rider L, Rodrigues LU, Gijón MA, Pac CT, Romero L, Cimic A, Sirintrapun SJ, Glodé LM, Eckel RH, Cramer SD.

Mol Cancer Ther. 2014 Oct;13(10):2361-71. doi: 10.1158/1535-7163.MCT-14-0183. Epub 2014 Aug 13.

46.

Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.

Rider LG, Yip AL, Horkayne-Szakaly I, Volochayev R, Shrader JA, Turner ML, Kong HH, Jain MS, Jansen AV, Oddis CV, Fleisher TA, Miller FW.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5):689-96. Epub 2014 Jul 28.

47.

Influence of stromal-epithelial interactions on androgen action.

Nieto CM, Rider LC, Cramer SD.

Endocr Relat Cancer. 2014 Aug;21(4):T147-60. doi: 10.1530/ERC-14-0138. Epub 2014 May 28. Review.

PMID:
24872510
48.

Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis.

Gan L, O'Hanlon TP, Gordon AS, Rider LG, Miller FW, Burbelo PD.

BMC Musculoskelet Disord. 2014 Mar 6;15:67. doi: 10.1186/1471-2474-15-67.

49.

Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.

Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC; RIM Study Group, Oddis CV.

Arthritis Rheumatol. 2014 Mar;66(3):740-9. doi: 10.1002/art.38270.

50.

Confusion concerning multiple versions of the childhood myositis assessment scale.

Huber AM, Lovell DJ, Pilkington CA, Rennebohm RM, Rider LG.

Arthritis Care Res (Hoboken). 2014 Apr;66(4):648. doi: 10.1002/acr.22239. No abstract available.

Supplemental Content

Support Center